

# A Pesquisa nos Diferentes Campos da Medicina Veterinária 3

---

Alécio Matos Pereira

Sara Silva Reis

Wesklen Marcelo Rocha Pereira

(Organizadores)



# A Pesquisa nos Diferentes Campos da Medicina Veterinária 3

---

Alécio Matos Pereira

Sara Silva Reis

Wesklen Marcelo Rocha Pereira

(Organizadores)



**Editora Chefe**

Prof<sup>a</sup> Dr<sup>a</sup> Antonella Carvalho de Oliveira

**Assistentes Editoriais**

Natalia Oliveira

Bruno Oliveira

Flávia Roberta Barão

**Bibliotecária**

Janaina Ramos

**Projeto Gráfico e Diagramação**

Natália Sandrini de Azevedo

Camila Alves de Cremo

Luiza Alves Batista

Maria Alice Pinheiro

**Imagens da Capa**

Shutterstock

**Edição de Arte**

Luiza Alves Batista

**Revisão**

Os Autores

2020 by Atena Editora

Copyright © Atena Editora

Copyright do Texto © 2020 Os autores

Copyright da Edição © 2020 Atena Editora

Direitos para esta edição cedidos à Atena

Editora pelos autores.



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação.

A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

**Conselho Editorial**

**Ciências Humanas e Sociais Aplicadas**

Prof. Dr. Alexandre Jose Schumacher – Instituto Federal de Educação, Ciência e Tecnologia do Paraná

Prof. Dr. Américo Junior Nunes da Silva – Universidade do Estado da Bahia

Prof. Dr. Antonio Carlos Frasson – Universidade Tecnológica Federal do Paraná

Prof. Dr. Antonio Gasparetto Júnior – Instituto Federal do Sudeste de Minas Gerais

Prof. Dr. Antonio Isidro-Filho – Universidade de Brasília  
Prof. Dr. Carlos Antonio de Souza Moraes – Universidade Federal Fluminense  
Prof<sup>a</sup> Dr<sup>a</sup> Cristina Gaio – Universidade de Lisboa  
Prof. Dr. Daniel Richard Sant’Ana – Universidade de Brasília  
Prof. Dr. Deyvison de Lima Oliveira – Universidade Federal de Rondônia  
Prof<sup>a</sup> Dr<sup>a</sup> Dilma Antunes Silva – Universidade Federal de São Paulo  
Prof. Dr. Edvaldo Antunes de Farias – Universidade Estácio de Sá  
Prof. Dr. Elson Ferreira Costa – Universidade do Estado do Pará  
Prof. Dr. Elio Martins Senhora – Universidade Federal de Roraima  
Prof. Dr. Gustavo Henrique Cepolini Ferreira – Universidade Estadual de Montes Claros  
Prof<sup>a</sup> Dr<sup>a</sup> Ivone Goulart Lopes – Istituto Internazionale delle Figlie di Maria Ausiliatrice  
Prof. Dr. Jadson Correia de Oliveira – Universidade Católica do Salvador  
Prof. Dr. Julio Candido de Meirelles Junior – Universidade Federal Fluminense  
Prof<sup>a</sup> Dr<sup>a</sup> Lina Maria Gonçalves – Universidade Federal do Tocantins  
Prof. Dr. Luis Ricardo Fernandes da Costa – Universidade Estadual de Montes Claros  
Prof<sup>a</sup> Dr<sup>a</sup> Natiéli Piovesan – Instituto Federal do Rio Grande do Norte  
Prof. Dr. Marcelo Pereira da Silva – Pontifícia Universidade Católica de Campinas  
Prof<sup>a</sup> Dr<sup>a</sup> Maria Luzia da Silva Santana – Universidade Federal de Mato Grosso do Sul  
Prof<sup>a</sup> Dr<sup>a</sup> Paola Andressa Scortegagna – Universidade Estadual de Ponta Grossa  
Prof<sup>a</sup> Dr<sup>a</sup> Rita de Cássia da Silva Oliveira – Universidade Estadual de Ponta Grossa  
Prof. Dr. Rui Maia Diamantino – Universidade Salvador  
Prof. Dr. Urandi João Rodrigues Junior – Universidade Federal do Oeste do Pará  
Prof<sup>a</sup> Dr<sup>a</sup> Vanessa Bordin Viera – Universidade Federal de Campina Grande  
Prof. Dr. William Cleber Domingues Silva – Universidade Federal Rural do Rio de Janeiro  
Prof. Dr. Willian Douglas Guilherme – Universidade Federal do Tocantins

### **Ciências Agrárias e Multidisciplinar**

Prof. Dr. Alexandre Igor Azevedo Pereira – Instituto Federal Goiano  
Prof<sup>a</sup> Dr<sup>a</sup> Carla Cristina Bauermann Brasil – Universidade Federal de Santa Maria  
Prof. Dr. Antonio Pasqualetto – Pontifícia Universidade Católica de Goiás  
Prof. Dr. Cleberton Correia Santos – Universidade Federal da Grande Dourados  
Prof<sup>a</sup> Dr<sup>a</sup> Daiane Garabeli Trojan – Universidade Norte do Paraná  
Prof<sup>a</sup> Dr<sup>a</sup> Diocléa Almeida Seabra Silva – Universidade Federal Rural da Amazônia  
Prof. Dr. Écio Souza Diniz – Universidade Federal de Viçosa  
Prof. Dr. Fábio Steiner – Universidade Estadual de Mato Grosso do Sul  
Prof. Dr. Fágner Cavalcante Patrocínio dos Santos – Universidade Federal do Ceará  
Prof<sup>a</sup> Dr<sup>a</sup> Girlene Santos de Souza – Universidade Federal do Recôncavo da Bahia  
Prof. Dr. Jael Soares Batista – Universidade Federal Rural do Semi-Árido  
Prof. Dr. Júlio César Ribeiro – Universidade Federal Rural do Rio de Janeiro  
Prof<sup>a</sup> Dr<sup>a</sup> Lina Raquel Santos Araújo – Universidade Estadual do Ceará  
Prof. Dr. Pedro Manuel Villa – Universidade Federal de Viçosa  
Prof<sup>a</sup> Dr<sup>a</sup> Raissa Rachel Salustriano da Silva Matos – Universidade Federal do Maranhão  
Prof. Dr. Ronilson Freitas de Souza – Universidade do Estado do Pará  
Prof<sup>a</sup> Dr<sup>a</sup> Talita de Santos Matos – Universidade Federal Rural do Rio de Janeiro  
Prof. Dr. Tiago da Silva Teófilo – Universidade Federal Rural do Semi-Árido  
Prof. Dr. Valdemar Antonio Paffaro Junior – Universidade Federal de Alfenas

## **Ciências Biológicas e da Saúde**

Prof. Dr. André Ribeiro da Silva – Universidade de Brasília  
Prof<sup>a</sup> Dr<sup>a</sup> Anelise Levay Murari – Universidade Federal de Pelotas  
Prof. Dr. Benedito Rodrigues da Silva Neto – Universidade Federal de Goiás  
Prof<sup>a</sup> Dr<sup>a</sup> Débora Luana Ribeiro Pessoa – Universidade Federal do Maranhão  
Prof. Dr. Douglas Siqueira de Almeida Chaves -Universidade Federal Rural do Rio de Janeiro  
Prof. Dr. Edson da Silva – Universidade Federal dos Vales do Jequitinhonha e Mucuri  
Prof<sup>a</sup> Dr<sup>a</sup> Eleuza Rodrigues Machado – Faculdade Anhanguera de Brasília  
Prof<sup>a</sup> Dr<sup>a</sup> Elane Schwinden Prudêncio – Universidade Federal de Santa Catarina  
Prof<sup>a</sup> Dr<sup>a</sup> Eysler Gonçalves Maia Brasil – Universidade da Integração Internacional da Lusofonia Afro-Brasileira  
Prof. Dr. Ferlando Lima Santos – Universidade Federal do Recôncavo da Bahia  
Prof<sup>a</sup> Dr<sup>a</sup> Gabriela Vieira do Amaral – Universidade de Vassouras  
Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria  
Prof. Dr. Helio Franklin Rodrigues de Almeida – Universidade Federal de Rondônia  
Prof<sup>a</sup> Dr<sup>a</sup> Iara Lúcia Tescarollo – Universidade São Francisco  
Prof. Dr. Igor Luiz Vieira de Lima Santos – Universidade Federal de Campina Grande  
Prof. Dr. Jefferson Thiago Souza – Universidade Estadual do Ceará  
Prof. Dr. Jesus Rodrigues Lemos – Universidade Federal do Piauí  
Prof. Dr. Jônatas de França Barros – Universidade Federal do Rio Grande do Norte  
Prof. Dr. José Max Barbosa de Oliveira Junior – Universidade Federal do Oeste do Pará  
Prof. Dr. Luís Paulo Souza e Souza – Universidade Federal do Amazonas  
Prof<sup>a</sup> Dr<sup>a</sup> Magnólia de Araújo Campos – Universidade Federal de Campina Grande  
Prof. Dr. Marcus Fernando da Silva Praxedes – Universidade Federal do Recôncavo da Bahia  
Prof<sup>a</sup> Dr<sup>a</sup> Maria Tatiane Gonçalves Sá – Universidade do Estado do Pará  
Prof<sup>a</sup> Dr<sup>a</sup> Mylena Andréa Oliveira Torres – Universidade Ceuma  
Prof<sup>a</sup> Dr<sup>a</sup> Natiéli Piovesan – Instituto Federal do Rio Grande do Norte  
Prof. Dr. Paulo Inada – Universidade Estadual de Maringá  
Prof. Dr. Rafael Henrique Silva – Hospital Universitário da Universidade Federal da Grande Dourados  
Prof<sup>a</sup> Dr<sup>a</sup> Regiane Luz Carvalho – Centro Universitário das Faculdades Associadas de Ensino  
Prof<sup>a</sup> Dr<sup>a</sup> Renata Mendes de Freitas – Universidade Federal de Juiz de Fora  
Prof<sup>a</sup> Dr<sup>a</sup> Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa  
Prof<sup>a</sup> Dr<sup>a</sup> Vanessa Bordin Viera – Universidade Federal de Campina Grande

## **Ciências Exatas e da Terra e Engenharias**

Prof. Dr. Adélio Alcino Sampaio Castro Machado – Universidade do Porto  
Prof. Dr. Carlos Eduardo Sanches de Andrade – Universidade Federal de Goiás  
Prof<sup>a</sup> Dr<sup>a</sup> Carmen Lúcia Voigt – Universidade Norte do Paraná  
Prof. Dr. Douglas Gonçalves da Silva – Universidade Estadual do Sudoeste da Bahia  
Prof. Dr. Elio Rufato Junior – Universidade Tecnológica Federal do Paraná  
Prof<sup>a</sup> Dr<sup>a</sup> Érica de Melo Azevedo – Instituto Federal do Rio de Janeiro  
Prof. Dr. Fabrício Menezes Ramos – Instituto Federal do Pará  
Prof<sup>a</sup> Dra. Jéssica Verger Nardeli – Universidade Estadual Paulista Júlio de Mesquita Filho  
Prof. Dr. Juliano Carlo Rufino de Freitas – Universidade Federal de Campina Grande

Profª Drª Luciana do Nascimento Mendes – Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Norte  
Prof. Dr. Marcelo Marques – Universidade Estadual de Maringá  
Profª Drª Neiva Maria de Almeida – Universidade Federal da Paraíba  
Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte  
Profª Drª Priscila Tessmer Scaglioni – Universidade Federal de Pelotas  
Prof. Dr. Takeshy Tachizawa – Faculdade de Campo Limpo Paulista

### **Linguística, Letras e Artes**

Profª Drª Adriana Demite Stephani – Universidade Federal do Tocantins  
Profª Drª Angeli Rose do Nascimento – Universidade Federal do Estado do Rio de Janeiro  
Profª Drª Carolina Fernandes da Silva Mandaji – Universidade Tecnológica Federal do Paraná  
Profª Drª Denise Rocha – Universidade Federal do Ceará  
Prof. Dr. Fabiano Tadeu Grazioli – Universidade Regional Integrada do Alto Uruguai e das Missões  
Prof. Dr. Gilmei Fleck – Universidade Estadual do Oeste do Paraná  
Profª Drª Keyla Christina Almeida Portela – Instituto Federal de Educação, Ciência e Tecnologia do Paraná  
Profª Drª Miranilde Oliveira Neves – Instituto de Educação, Ciência e Tecnologia do Pará  
Profª Drª Sandra Regina Gardacho Pietrobon – Universidade Estadual do Centro-Oeste  
Profª Drª Sheila Marta Carregosa Rocha – Universidade do Estado da Bahia

### **Conselho Técnico Científico**

Prof. Me. Abrão Carvalho Nogueira – Universidade Federal do Espírito Santo  
Prof. Me. Adalberto Zorzo – Centro Estadual de Educação Tecnológica Paula Souza  
Prof. Dr. Adaylson Wagner Sousa de Vasconcelos – Ordem dos Advogados do Brasil/Seccional Paraíba  
Prof. Dr. Adilson Tadeu Basquerote Silva – Universidade para o Desenvolvimento do Alto Vale do Itajaí  
Prof. Me. Aleksandro Teixeira Ribeiro – Centro Universitário Internacional  
Prof. Me. André Flávio Gonçalves Silva – Universidade Federal do Maranhão  
Profª Ma. Andréa Cristina Marques de Araújo – Universidade Fernando Pessoa  
Profª Drª Andreza Lopes – Instituto de Pesquisa e Desenvolvimento Acadêmico  
Profª Drª Andrezza Miguel da Silva – Faculdade da Amazônia  
Profª Ma. Anelisa Mota Gregoleti – Universidade Estadual de Maringá  
Profª Ma. Anne Karynne da Silva Barbosa – Universidade Federal do Maranhão  
Prof. Dr. Antonio Hot Pereira de Faria – Polícia Militar de Minas Gerais  
Prof. Me. Armando Dias Duarte – Universidade Federal de Pernambuco  
Profª Ma. Bianca Camargo Martins – UniCesumar  
Profª Ma. Carolina Shimomura Nanya – Universidade Federal de São Carlos  
Prof. Me. Carlos Antônio dos Santos – Universidade Federal Rural do Rio de Janeiro  
Prof. Ma. Cláudia de Araújo Marques – Faculdade de Música do Espírito Santo  
Profª Drª Cláudia Taís Siqueira Cagliari – Centro Universitário Dinâmica das Cataratas  
Prof. Me. Clécio Danilo Dias da Silva – Universidade Federal do Rio Grande do Norte  
Prof. Me. Daniel da Silva Miranda – Universidade Federal do Pará  
Profª Ma. Daniela da Silva Rodrigues – Universidade de Brasília  
Profª Ma. Daniela Remião de Macedo – Universidade de Lisboa

Profª Ma. Dayane de Melo Barros – Universidade Federal de Pernambuco  
Prof. Me. Douglas Santos Mezacas – Universidade Estadual de Goiás  
Prof. Me. Edevaldo de Castro Monteiro – Embrapa Agrobiologia  
Prof. Me. Eduardo Gomes de Oliveira – Faculdades Unificadas Doctum de Cataguases  
Prof. Me. Eduardo Henrique Ferreira – Faculdade Pitágoras de Londrina  
Prof. Dr. Edwaldo Costa – Marinha do Brasil  
Prof. Me. Eliel Constantino da Silva – Universidade Estadual Paulista Júlio de Mesquita  
Prof. Me. Ernane Rosa Martins – Instituto Federal de Educação, Ciência e Tecnologia de Goiás  
Prof. Me. Euvaldo de Sousa Costa Junior – Prefeitura Municipal de São João do Piauí  
Profª Ma. Fabiana Coelho Couto Rocha Corrêa – Centro Universitário Estácio Juiz de Fora  
Prof. Me. Felipe da Costa Negrão – Universidade Federal do Amazonas  
Profª Drª Germana Ponce de Leon Ramírez – Centro Universitário Adventista de São Paulo  
Prof. Me. Gevair Campos – Instituto Mineiro de Agropecuária  
Prof. Me. Givanildo de Oliveira Santos – Secretaria da Educação de Goiás  
Prof. Dr. Guilherme Renato Gomes – Universidade Norte do Paraná Prof. Me. Gustavo Krahil – Universidade do Oeste de Santa Catarina  
Prof. Me. Helton Rangel Coutinho Junior – Tribunal de Justiça do Estado do Rio de Janeiro  
Profª Ma. Isabelle Cerqueira Sousa – Universidade de Fortaleza  
Profª Ma. Jaqueline Oliveira Rezende – Universidade Federal de Uberlândia  
Prof. Me. Javier Antonio Albornoz – University of Miami and Miami Dade College  
Prof. Me. Jhonatan da Silva Lima – Universidade Federal do Pará  
Prof. Dr. José Carlos da Silva Mendes – Instituto de Psicologia Cognitiva, Desenvolvimento Humano e Social  
Prof. Me. Jose Elyton Batista dos Santos – Universidade Federal de Sergipe  
Prof. Me. José Luiz Leonardo de Araujo Pimenta – Instituto Nacional de Investigación Agropecuaria Uruguay  
Prof. Me. José Messias Ribeiro Júnior – Instituto Federal de Educação Tecnológica de Pernambuco  
Profª Drª Juliana Santana de Curcio – Universidade Federal de Goiás  
Profª Ma. Juliana Thaisa Rodrigues Pacheco – Universidade Estadual de Ponta Grossa  
Profª Drª Kamilly Souza do Vale – Núcleo de Pesquisas Fenomenológicas/UFPA  
Prof. Dr. Kárpio Márcio de Siqueira – Universidade do Estado da Bahia  
Profª Drª Karina de Araújo Dias – Prefeitura Municipal de Florianópolis  
Prof. Dr. Lázaro Castro Silva Nascimento – Laboratório de Fenomenologia & Subjetividade/UFPR  
Prof. Me. Leonardo Tullio – Universidade Estadual de Ponta Grossa  
Profª Ma. Lilian Coelho de Freitas – Instituto Federal do Pará  
Profª Ma. Liliani Aparecida Sereno Fontes de Medeiros – Consórcio CEDERJ  
Profª Drª Lívia do Carmo Silva – Universidade Federal de Goiás  
Prof. Dr. Lucio Marques Vieira Souza – Secretaria de Estado da Educação, do Esporte e da Cultura de Sergipe  
Prof. Me. Luis Henrique Almeida Castro – Universidade Federal da Grande Dourados  
Prof. Dr. Luan Vinicius Bernardelli – Universidade Estadual do Paraná  
Prof. Dr. Michel da Costa – Universidade Metropolitana de Santos  
Prof. Dr. Marcelo Máximo Purificação – Fundação Integrada Municipal de Ensino Superior

Prof. Me. Marcos Aurelio Alves e Silva – Instituto Federal de Educação, Ciência e Tecnologia de São Paulo  
Profª Ma. Maria Elanny Damasceno Silva – Universidade Federal do Ceará  
Profª Ma. Marileila Marques Toledo – Universidade Federal dos Vales do Jequitinhonha e Mucuri  
Prof. Me. Ricardo Sérgio da Silva – Universidade Federal de Pernambuco  
Profª Ma. Renata Luciane Polsaque Young Blood – UniSecal  
Prof. Me. Robson Lucas Soares da Silva – Universidade Federal da Paraíba  
Prof. Me. Sebastião André Barbosa Junior – Universidade Federal Rural de Pernambuco  
Profª Ma. Silene Ribeiro Miranda Barbosa – Consultoria Brasileira de Ensino, Pesquisa e Extensão  
Profª Ma. Solange Aparecida de Souza Monteiro – Instituto Federal de São Paulo  
Prof. Me. Tallys Newton Fernandes de Matos – Faculdade Regional Jaguaribana  
Profª Ma. Thatianny Jasmine Castro Martins de Carvalho – Universidade Federal do Piauí  
Prof. Me. Tiago Silvio Dedoné – Colégio ECEL Positivo  
Prof. Dr. Welleson Feitosa Gazel – Universidade Paulista

**Editora Chefe:** Prof<sup>a</sup> Dr<sup>a</sup> Antonella Carvalho de Oliveira  
**Bibliotecária:** Janaina Ramos  
**Diagramação:** Camila Alves de Cremo  
**Correção:** Vanessa Mottin de Oliveira Batista  
**Edição de Arte:** Luiza Alves Batista  
**Revisão:** Os Autores  
**Organizadores:** Alécio Matos Pereira  
Sara Silva Reis  
Wesklen Marcelo Rocha Pereira

**Dados Internacionais de Catalogação na Publicação (CIP)**

P474 A pesquisa nos diferentes campos da medicina veterinária 3 / Organizadores Alécio Matos Pereira, Sara Silva Reis, Wesklen Marcelo Rocha Pereira. – Ponta Grossa - PR: Atena, 2020.

Formato: PDF  
Requisitos de sistema: Adobe Acrobat Reader  
Modo de acesso: World Wide Web  
Inclui bibliografia  
ISBN 978-65-5706-654-6  
DOI 10.22533/at.ed.546200712

1. Medicina veterinária. 2. Pesquisa. I. Pereira, Alécio Matos (Organizador). II. Silva Reis, Sara (Organizadora). III. Pereira, Wesklen Marcelo Rocha (Organizador). IV. Título. CDD 636.089

**Elaborado por Bibliotecária Janaina Ramos – CRB-8/9166**

**Atena Editora**

Ponta Grossa – Paraná – Brasil

Telefone: +55 (42) 3323-5493

[www.atenaeditora.com.br](http://www.atenaeditora.com.br)

contato@atenaeditora.com.br

## **DECLARAÇÃO DOS AUTORES**

Os autores desta obra: 1. Atestam não possuir qualquer interesse comercial que constitua um conflito de interesses em relação ao artigo científico publicado; 2. Declararam que participaram ativamente da construção dos respectivos manuscritos, preferencialmente na: a) Concepção do estudo, e/ou aquisição de dados, e/ou análise e interpretação de dados; b) Elaboração do artigo ou revisão com vistas a tornar o material intelectualmente relevante; c) Aprovação final do manuscrito para submissão.; 3. Certificam que os artigos científicos publicados estão completamente isentos de dados e/ou resultados fraudulentos.

## **APRESENTAÇÃO**

O livro abrange temas relevantes relacionados a saúde animal, parasitologia, comportamento animal e produção de forragens. E estão divididos em volume II e volume III somando 52 capítulos. Nestes foram descritos relato de caso, experimentos e revisões. Que contém informações importantes para o entendimento do leitor, proporcionando uma visão clara e completa de todo conteúdo a ser abordado. No volume II e III, estão descritos assuntos como o comportamento, cognição e aprendizagem em cães, avaliação de carrapaticidas químicos, produção de forragem, coccidiose aviária, diagnóstico de tumores de pele em animais domésticos entre outros.

Os estudantes dos cursos das agrárias têm a sua disposição uma literatura científica ampla e aprofundada sobre os assuntos de maior vigência na atualidade. É um livro que aborda as mais diversas áreas da Medicina Veterinária e da produção animal, tornando os seus capítulos indispensáveis para uma atualização dos profissionais da área.

Nas últimas décadas houve grande aumento no número de grupos de pesquisa e publicações sobre comportamento, cognição e bem-estar de cães. Trazendo o foco nos novos conhecimentos gerados, nas dificuldades de compreensão desse conhecimento e as iniciativas que parecem poder suplantar as dificuldades.

Com tudo, a diversidade de assuntos abordados nos volumes II e III apresentam capítulos com pesquisas, relatos, objetivos e resultados, desenvolvidos por diversos pesquisadores, professores, profissionais e estudantes. Como uma maneira de expandir a pesquisa científica como uma fonte importante para auxiliar na atualização de todos que buscam uma fonte segura e atualizadas sobre a ciência animal.

Alécio Matos Pereira  
Sara Silva Reis  
Wesklen Marcelo Rocha Pereira

## SUMÁRIO

### CAPÍTULO 1..... 1

#### ADAPTABILIDADE DE CAPRINOS ANGLO-NUBIANA E BOER ÀS CONDIÇÕES CLIMÁTICAS DO MUNICÍPIO DE CHAPADINHA-MA

Sara Silva Reis  
Alécio Matos Pereira  
Wesklen Marcelo Pereira Rocha  
Ayszanalia Silva de Aguiar  
Julyana Barbosa Carvalho Silva  
Isaias Viana da Silva  
Maria das Dores Alves de Oliveira  
Nágila Maria de Carvalho Almeida  
André Alves de Sousa  
Arlan Araujo Rodrigues

**DOI 10.22533/at.ed.5462007121**

### CAPÍTULO 2..... 10

#### INCIDÊNCIA DE ERLIQUIOSE CANINA E COINFECÇÕES POR *Anaplasma spp.* E *Leishmania spp.* NO MUNICÍPIO DE FLORIANO-PI, BRASIL

Pedro Ferreira de Sousa Junior  
Raffael Oliveira Eufrasio  
Cosme Nogueira da Silva  
Pietra Roanny Costa Mota Sousa  
Lauanne Rodrigues Barros  
Thales Rodrigues Costa  
Luís Eduardo Leite Leão Martins  
Raylson Pereira de Oliveira  
José Pires de Carvalho Neto  
Glenda Lídice de Oliveira Cortez Marinho  
David Germano Gonçalves Schwarz  
Márcia Paula Oliveira Farias

**DOI 10.22533/at.ed.5462007122**

### CAPÍTULO 3..... 19

#### INFUSÃO CONTÍNUA DE NOREPINEFRINA NO CONTROLE DE HIPOTENSÃO TRANS E PÓS-OPERATÓRIO DE FELINO: RELATO DE CASO

Isabela Nicoletti Fávero  
Camila Feltrin Giglio  
Rochelle Gorczak

**DOI 10.22533/at.ed.5462007123**

### CAPÍTULO 4..... 31

#### INGESTÃO DE MÚLTIPLAS PEDRAS BRITA POR UM CÃO – RELATO DE CASO

Raylanne Letícia Pessoa Sousa  
Ryshely Sonaly de Moura Borges  
Moisés Dantas Tertulino  
Araceli Alves Dutra

Darlla Whaianny Fernandes de Lima

Camila Carneiro Araújo

Eraldo Barbosa Calado

**DOI 10.22533/at.ed.5462007124**

**CAPÍTULO 5..... 38**

**MIELOMA MÚLTIPLO EM CÃO – RELATO DE CASO**

Luana Lopes Patente

Michele Legnaro Canteiro

Milene Letícia Bastos de Souza

Elizabeth Bohland

**DOI 10.22533/at.ed.5462007125**

**CAPÍTULO 6..... 42**

**NEURITE POR DOENÇA DE MAREK EM GALINHAS CAIPIRAS**

Vitor de Moraes Pina de Carvalho

Alessandra Estrela-Lima

Natasha Dórea da Silva Azevedo

Flávia Roberta Pereira Abbude-Carvalho

Elainne Maria Beanes da Silva Santos

Gabriel Saraiva Diniz Gonçalves

Danielle Nascimento Silva

Lia Muniz Barreto Fernandes

Thanielle Novaes Fontes

Eduardo Luiz Moreira Trindade

Isabella Neves Finamori França Polonio

Marilaine Carlos de Sousa

**DOI 10.22533/at.ed.5462007126**

**CAPÍTULO 7..... 50**

**OCORRÊNCIA DE *MYCOBACTERIUM AVIUM* SUBSP. *PARATUBERCULOSIS* VIÁVEL DO TIPO *CATTLE* SUBTIPO *BISON* EM QUEIJO COALHO DE BÚFALA PROVENIENTE DE ALAGOAS, BRASIL**

Pedro Paulo Feitosa de Albuquerque

Marilene de Farias Brito

Erika Fernanda Torres Samico- Fernandes

José Wilton Pinheiro Junior

Rinaldo Aparecido Mota

**DOI 10.22533/at.ed.5462007127**

**CAPÍTULO 8..... 60**

**PROCESSOS DE VITRIFICAÇÃO DE OÓCITOS E EMBRIÕES: O QUE VOCÊ PRECISA SABER**

Mariana Mendonça Maia Cavalcante

Marcio Calixto Matias

Agnelo Douglas do Nascimento Junior

Sandra Simmone de Barros Lima

Simone Firmino dos Santos

Gilsan Aparecida de Oliveira  
Raíssa Karolliny Salgueiro Cruz  
Zelma Holanda do Nascimento  
Camila Calado de Vasconcelos  
Valesca Barreto Luz

**DOI 10.22533/at.ed.5462007128**

**CAPÍTULO 9..... 70**

OVINOCULTURA: PRINCIPAIS HELMINTOS GASTRINTESTINAIS  
ENCONTRADOS NA CAMPANHA GAÚCHA

Brenda Luciana Alves da Silva  
Mikaele Simas Santos  
Gustavo Freitas Lopes  
Gladis Ferreira Corrêa  
Lourdes Caruccio Hirschmann  
Marcele Ribeiro Corrêa  
Anelise Afonso Martins

**DOI 10.22533/at.ed.5462007129**

**CAPÍTULO 10..... 77**

OZONIOTERAPIA NO TRATAMENTO DE INSUFICIÊNCIA RENAL GRAU III E  
ASSOCIAÇÕES INTEGRATIVAS- Relato de Caso

Daniela Franco Lopes  
Fernanda Suenson Martarella  
Guilherme Augusto Oliveira Barbosa  
Matheus Corsini Pilla  
Ana Cláudia Benedictis Andreta

**DOI 10.22533/at.ed.54620071210**

**CAPÍTULO 11 ..... 84**

PASSADO, PRESENTE E FUTURO NA PESQUISA DE COCCIDIOSE AVIÁRIA

Fabiano Fabri  
Marco Antonio de Andrade Belo

**DOI 10.22533/at.ed.54620071211**

**CAPÍTULO 12..... 97**

PODODERMATITE SÉPTICA COM ROTAÇÃO DE FALANGE DISTAL EM EQUINO  
– RELATO DE CASO

Daniela Scantamburlo Denadai  
Fernando Vissani Fernandes  
Daniela Bernadete Rozza  
Paulo Sergio Patto dos Santos  
Juliana Regina Peiró  
Flávia de Almeida Lucas

**DOI 10.22533/at.ed.54620071212**

**CAPÍTULO 13..... 102**

PREVALÊNCIA E FATORES DE RISCO ASSOCIADOS À INFECÇÃO PELO

## VÍRUS DA ARTRITE ENCEFALITE CAPRINA EM CAPRINOS NO ESTADO DO MARANHÃO

Ynady Ferreira Costa  
Laudeci Pires Melo  
Tânia Maria Duarte Silva  
Nancyleni Pinto Chaves Bezerra  
Daniel Praseres Chaves  
Adriana Prazeres Paixão  
Cristian Alex Aquino Lima  
Carla Janaina Rebouças Marques do Rosário  
Ferdinan Almeida Melo

**DOI 10.22533/at.ed.54620071213**

## CAPÍTULO 14.....110

### PRINCIPAIS AGENTES MICROBIANOS DA PIOMETRA CANINA

Camila Falasca  
Amanda Stephanie da Silva Buchud  
Rômulo Francis Stangari Lot

**DOI 10.22533/at.ed.54620071214**

## CAPÍTULO 15.....116

### PROBLEMAS RESPIRATÓRIOS ASSOCIADOS À EFICÁCIA DO ÁCIDO PERACÉTICO DIAGNOSTICADOS EM CÃES E GATOS

Ester Antonia Bianchet  
Fernanda Canello Bandiera  
Daniele Cristine Beuron

**DOI 10.22533/at.ed.54620071215**

## CAPÍTULO 16.....126

### PSEUDO-HERMAFRODITA MASCULINO NA ESPÉCIE SUÍNA (*SUS SCROFA DOMESTICUS*)

Carla Fredrichsen Moya  
Willian Daniel Pavan  
Milena Pontarolo Machado  
Polyana Caroline Pissinato Esquerdo Amaro Pedroso  
Jayme Augusto Peres

**DOI 10.22533/at.ed.54620071216**

## CAPÍTULO 17.....132

### RABDOMIOSSARCOMA EMBRIONÁRIO EM VESÍCULA URINÁRIA DE CÃO COM OITO MESES DE IDADE – RELATO DE CASO

Marcos Piazzolo  
Olicies da Cunha

**DOI 10.22533/at.ed.54620071217**

## CAPÍTULO 18.....137

### RELATO DE EXPERIÊNCIA DE TIMPANISMO GASOSO EM NOVILHA DA

## UNIDADE DIDÁTICA DE BOVINOCULTURA DE LEITE DA UNICENTRO

Bruna Rafaela Buss

Bruna Los

Gabriel Vinicius Bet Flores

Mariane Roepke

Helcya Mime Ishiy Hulse

**DOI 10.22533/at.ed.54620071218**

### **CAPÍTULO 19..... 145**

#### SCHWANNOMA MALIGNO CANINO EM MEMBRO PÉLVICO – RELATO DE CASO

Gabriela Carvalho Monteiro

Juliano Jácomo Mendes Silotti

Juliana Gomes Braga

Marcus Vinícius Lima David

Cinthia Oliveira de Araújo Barreto

Marília Carneiro de Araújo Machado

**DOI 10.22533/at.ed.54620071219**

### **CAPÍTULO 20..... 152**

#### SINDROME NEUROLÓGICA DA ENCEFALOPATIA ESPONGIFORME BOVINA

Dâmaris Oliveira Bezerra do Nascimento

Marco Antonio de Andrade Belo

**DOI 10.22533/at.ed.54620071220**

### **CAPÍTULO 21..... 161**

#### TRATAMENTO DE FERIDA ABERTA EM EQUINO UTILIZANDO INFUSÃO DE *Stryphnodendron adstringens* ASSOCIADA A AÇÚCAR CRISTAL – RELATO DE CASO

Patrícia Natalicia Mendes de Almeida

Henrique Fernandes Giovanoni

Rodrigo Fernandes Giovanoni

**DOI 10.22533/at.ed.54620071221**

### **CAPÍTULO 22..... 173**

#### TRATAMENTO DE MASTITE CLÍNICA E SUBCLÍNICA EM VACAS LEITEIRAS COM GÁS OZÔNIO INTRA-MAMÁRIO

Caio Vinicius Martins

Natan de Jesus Laudino

Ana Caroline Jorge Menezes

Thalita Masoti Blankenheim

**DOI 10.22533/at.ed.54620071222**

### **CAPÍTULO 23..... 183**

#### TREATMENT OF CANINE OSTEOSARCOMA USING AUTOLOGOUS ACTIVE IMMUNOTHERAPY WITH OR WITHOUT SURGERY

Patrick Frayssinet

Didier Mathon

Michel Simonet  
Jean Louis Trouillet  
Valérie Mathon  
Nicole Rouquet

**DOI 10.22533/at.ed.54620071223**

**CAPÍTULO 24..... 198**

**URINÁLISE DE *BRADYPUST VARIEGATUS* EM CATIVEIRO**

Marina Sette Camara Benarrós  
Vitória Farias Luz  
Tatiana Andrade Figueiredo  
Ana Silvia Sardinha Ribeiro

**DOI 10.22533/at.ed.54620071224**

**CAPÍTULO 25..... 209**

**USE OF ENVIRONMENTAL AND GENETIC DESCRIPTORS TO INTEGRATE HERDS OF SHEEP**

Jorge Osorio Avalos  
Pliego Esquila Marcelino  
González Ronquillo Manuel  
Robles Jiménez Lizbeth Esmeralda  
Castelán Ortega Octavio Alonso

**DOI 10.22533/at.ed.54620071225**

**CAPÍTULO 26..... 229**

**USO DA CITOPATOLOGIA PARA O DIAGNÓSTICO DE TUMORES DE PELE EM ANIMAIS DOMÉSTICOS**

João Rogério Centenaro  
Larissa Grunitzky  
Natasha Rocha da Silva  
Paulo Henrique Braz

**DOI 10.22533/at.ed.54620071226**

**SOBRE OS ORGANIZADORES ..... 240**

**ÍNDICE REMISSÍVO ..... 241**

# CAPÍTULO 23

## TREATMENT OF CANINE OSTEOSARCOMA USING AUTOLOGOUS ACTIVE IMMUNOTHERAPY WITH OR WITHOUT SURGERY

Data de aceite: 01/12/2020

Data de submissão : 17/09/2020

### Patrick Frayssinet

Urodelia, Rte de St Thomas, 31470 St Lys,  
France

### Didier Mathon

Unité de Recherche Clinique, Ecole Nationale  
Vétérinaire de Toulouse, Chemin des Capelles,  
31400 Toulouse, France

### Michel Simonet

Clinique des côtes de Nuit, Rte de Dijon, 29  
Nuit St Georges, France

### Jean Louis Trouillet

Clinique Vétérinaire, Rue François Couperin,  
Castres, France

### Valérie Mathon

Clinique vétérinaire de La Battière, Rte de  
Toulouse, Plaisance du Touch, France

### Nicole Rouquet

Urodelia, Rte de St Thomas, 31470 St Lys,  
France

**ABSTRACT:** Canine osteosarcoma is a disease having a very poor short term prognosis and is a good model for the study of the human disease. It was demonstrated that both in the human and canine disease heat shock proteins (HSPs) were synthesized by the cancer cells. These molecules are chaperone molecules for the cell peptides and also are involved in their associated peptide

presentation to the lymphocytes. We developed a method for immune system stimulation based on the purification of intratumoral autologous heat shock proteins (HSPs) which are then re injected in the subcutaneous tissue with a phosphocalcic particulate adjuvant. We tested this method on 12 dogs and the overall survival (OS) and progression free survival (PFS) were measured. Two groups can be differentiated. A long survival group ( $n=7$ ) and a short survival group ( $n=3$ ) in which two dogs were killed for pain while their overall conditions was good. In the long survival group, three dogs were amputated and showed a longer OS than non amputated. No secondary effect was observed following the injections. The OS and PFS were greatly improved compared to the data given in the literature in the long survival group. In conclusions, these results suggest that this protocol could be of interest in human medicine associated to classical radio and chemotherapy.

**KEYWORDS:** Osteosarcoma, immunotherapy, vaccine.

## TRATAMENTO DO OSTEOSSARCOMA CANINO COM IMUNOTERAPIA AUTÓLOGA ATIVA COM OU SEM CIRURGIA

**RESUMO :** O osteossarcoma canino é uma doença com um prognóstico de curto prazo muito ruim e é um bom modelo para doença humana. Em humanos e cães, as proteínas de choque térmico (HSPs) são sintetizadas por células cancerosas. Essas moléculas, além do papel de chaperonas de peptídeos celulares, desempenham um papel importante na apresentação de抗ígenos às

células imunocompetentes. Desenvolvemos um método de estimulação do sistema imunológico contra células tumorais por purificação de proteínas autólogas de choque térmico intratumoral e sua administração subcutânea acompanhada por adjuvante fosfocálcico. Testamos este método em uma série de 12 cães com osteossarcomas para os quais a sobrevida global (OS), bem como a sobrevida livre de progressão da doença (PFS) foram medidas. Dois cães se perderam de vista. Nos 10 cães restantes, dois grupos foram individualizados. Um grupo ( $n = 7$ ) com vida longa e outro ( $n = 3$ ) com vida curta, no qual dois cães foram sacrificados por um problema de dor quando seu estado geral não justificava a eutanásia. No grupo de cães com longa sobrevida, 3 foram amputados e tiveram uma sobrevida maior do que aqueles sem amputação. Nenhum efeito colateral foi observado em nenhum dos cães. Portanto, parece que esses dois parâmetros foram significativamente aumentados em comparação com os dados da literatura no grupo de sobrevida longa. Em conclusão, esses resultados sugerem que esta técnica de estimulação do sistema imunológico pode ser de interesse em humanos associada ao tratamento quimio / radioterápico.

**PALAVRAS-CHAVE:** Osteossarcoma, imunoterapia, vacina.

## 1 | INTRODUCTION

In human medicine, osteosarcoma is the most common, although rare, primary bone tumor. It still has a poor prognosis despite the improvement made in recent years by chemotherapy combined with major surgery. This pathology is all the more worrying as it affects a young population. Canine osteosarcoma shares many points in common with humans and can thus constitute an interesting model. Clinically its presentation and its evolution in particular its capacity to produce metastases are very similar, biologically many alterations of certain cell signaling pathways are found in both cases as well as the overexpression of certain oncogenes [1].

From a veterinary perspective, most dogs are seen at an advanced stage that is already metastatic or micrometastatic, and in daily veterinary practice very few animals undergo chemotherapy. The treatment of choice remains amputation which somewhat improves the prognosis since the median survival of amputated dogs is 5 months [2]. The histological classification makes it possible to distinguish 4 stages of increasing aggressiveness. The overall survival of the dog if the pain does not justify euthanasia remains from a few days to a few weeks [3] without specific treatment.

In recent years, numerous teams have developed techniques for stimulating the immune system in order to fight specifically against tumor cells with few side effects, in particular by preserving rapidly renewing cells which are the preferred target of chemotherapy treatments [4]. Various techniques for activating the immune system have been developed and can be grouped into 2 broad categories.

Passive immunotherapy is widely used today. It uses monoclonal antibodies whether or not associated with immunotoxins or radioelements to destroy the target

cell. These monoclonal antibodies, when not associated with any molecule or toxic element, can be used to block a receptor or an informative molecule such as anti-VEGFs that limit tumor vascularization [5, 6]. There are also techniques using non-specific stimulants such as GM-CSF [7, 8], IL-2 [9], and BCG [10].

On the contrary, active immunotherapy aims to stimulate the patient's immune system and in particular his cellular immunity (CD8) against antigens of tumor cells. Activation of CD8 T lymphocytes against tumor cells takes place through the stimulation and maturation of antigen presenting cells (APCs), mainly macrophages and dendritic cells which will shape tumor antigens and express them on the cell surface associated to MHC class I proteins to present them to CD8s [11, 12]. Stimulation of autologous dendritic cells *in vitro* by tumor antigens followed by their reinjection has been widely used for various types of tumors with varying results [13, 14]. The collection and *in vitro* amplification of T lymphocytes infiltrated into tumors can also be considered for osteosarcomas [15] as well as the injection of NK cells which have the capacity to fight tumor cells without being «educated».

It is known that tumor cells are extremely genetically unstable cells which synthesize many abnormal proteins, several dozens to several hundred. The genetic instability of the cancer cell means that these abnormal proteins are not the same throughout the course of the tumor and they differ from patient to patient [16, 17]. There are, however, proteins that are abnormal or that are not normally expressed in the cell line from which the cancer cell is derived, which are found almost systematically in a particular pathology. These latter proteins have made it possible to imagine therapeutic monoprotein vaccines that have given poor results in reason of the constant cell mutation.

Vaccines with many antigenic patterns appear to be more interesting because they provide many elements of cellular identity and the recognition of tumor cells by CD8 is less sensitive to point mutations. We have developed a process for the preparation of therapeutic vaccines containing numerous antigenic motifs by isolating stress proteins from osteosarcomas. Gp96 and Hsp70 are indeed found in large quantities in tumor cells, probably due to the cellular suffering induced by the abnormal metabolism of these cells [18]. These are chaperone molecules which are therefore associated with almost all the peptides synthesized by the cell [19, 20, 21, 22]. They are also involved in the presentation of these peptides associated with the surface of APCs and thus participate in monitoring the immune survey of any cell transformation by the immune system. In both dogs and humans, transformed osteosarcoma cells have been shown to produce these proteins in large quantities regardless of the histological type [23, 24, 25].

We selected a series of 12 dogs consulting for appendicular or flat bone osteosarcoma. The stress proteins have been isolated in order to constitute

autologous vaccines. They are purified by adsorption on columns containing micro / nanoparticles of calcium phosphates which are then injected into the same animal to stimulate the immune system. The aim of this study was to investigate the feasibility of the protocol in veterinary practice, to assess the absence of side effects as well as overall survival and the period of absence of disease progression. This study also provides a model of immune stimulation against a solid tumor that can be used in human medicine.

## 2 | MATERIALS AND METHODS

### 2.1 Animals treated

The dogs were selected after a consultation motivated by lameness and / or swelling having led to a X rays exploration showing an image of bone proliferation associated with lysis. The inclusion criteria are a general condition preserved suggesting a survival of more than 5 weeks, a count formula within the normal limits, refusal of chemotherapy treatment by the owner, owner able to monitor his dog and bring him back on a fixed date, and signing an informed consent.

A regional extension assessment to search for lymphadenopathy is implemented and a chest x-ray is systematically performed at the first visit. At each visit for an injection of a dose of immunotherapy, the size of the inflammatory area is assessed and noted. An extension assessment is done if clinical signs appear. The animals all received nonsteroidal anti-inflammatory drugs and non-morphine analgesics on demand. Three dogs were amputated at the request of the owner before the beginning of the vaccine protocol without reconstructive surgery or devices.

The progression free survival time (PFS progression free survival) is taken from the date of the first vaccine to a sign of disease progression (tumor growth, metastasis or fracture). A complete response was defined as a disappearance of clinical signs for at least 4 weeks, a partial response as a reduction in the perpendicular diameters of the lesions by more than 50% for 4 weeks, a minor response as a reduction in these same diameters between 25 and 50%, stable disease such as less than 25% reduction without onset of metastasis and progression such as onset of metastasis or growth of diameters greater than 25%

### 2.2 Dose preparation

Under general anesthesia, a tumor biopsy is taken with a cortical to cortical Michelet trephine. A fragment of the sample is fixed in a formaldehyde solution and sent to the pathological anatomy laboratory. The rest (about 0.5 cm<sup>3</sup>) is sterilized in a dry tube and frozen at -18 ° C.

After the histological diagnosis is made, the frozen fragment is ground in a ball homogenizer (Setis, France), the ground material is diluted in 2 cm<sup>3</sup> of NaHCO<sub>3</sub> (30 mM) and centrifuged at 5000 g to remove cell debris. The supernatant is diluted to 50% with a supersaturated sodium nitrate solution, centrifuged at 5000 g. The supernatant is removed, the protein pellet resuspended in a 20 mM phosphate buffer solution, pH 6.8. The solution is then passed through a column containing 200 mg of calcium hydroxyapatite powder. The column is washed with 10 ml of 50 mM phosphate buffer, Ph 6.8. The powder is then suspended in a solution of 2% carboxymethylcellulose in 20 mM phosphate buffer, pH 6.8 and distributed so as to represent a volume of 0.5 ml per dose in 1 ml syringes.

The doses are injected subcutaneously at a frequency of 1 per week for 4 weeks then once per month for 4 months.

### 2.3 Dose control

Electrophoresis and Western blotting as well as a dot blot are performed for each tumor.

The electrophoresis is performed on NuPage gels (in vitroGen, France) according to the manufacturer's recommendations (InvitroGen, France). Briefly, the powder residues in the chromatography column are washed in 0.5 ml of 0.5M NaCl. 20 µl are mixed with 10 µl of detergent and 5 µl of reducing agent (in vitroGen, France). 10 µl of this solution are introduced into the wells of the gel and passed through a 200 V field at 120 mA for 30 min. The gels are stained with silver nitrate.

Dot blot: 10 µl of the vaccine solution are applied to a nitrocellulose membrane and left to dry in the open air. Once dry, the membrane is washed with a blocking solution (1% BSA in PBS) then with a solution of Tris buffer (pH 7.4) containing 0.5% of detergent Tween 20. The membrane is then incubated with primary antibody one hour at room temperature (anti-gp96, anti-HSP70, stressgen-US) before being washed in the same buffer. The membrane is incubated for 30 minutes with the secondary antibody labeled with an alkaline phosphatase and then washed with the buffer before adding a developer for alkaline phosphatase.

### 2.4 Binding of vaccine proteins on cd91

The RAW264 (ATCC) cell line is characterized by the presence of a large number of cd91 receptors on the surface of the cell membrane, these receptors being specific for gp96 and hsp70. For each animal, the vaccine proteins are associated with a peroxidase and RAW264 cells are cultured in the presence of the labeled proteins after having the membrane cd91 blocked or not by an anti cd91 antibody (invitroGen). The cells are cultured in 25cm<sup>2</sup> culture dishes (Falcon, France) in a culture medium of DMEM type supplemented with glutamine (Sigma, France) and with 5% fetal calf serum (Sigma, France). They are incubated at 37 °

C, in an atmosphere of 98% humidity and 5% CO<sub>2</sub>. When they reach 70% of their confluence, the cells are washed in PBS and fixed in ethanol. The labeled proteins are incubated overnight with the cells. The blocking of cd91 is done by incubating the cells for two hours in an antibody solution diluted 1/1000 in a blocking solution (immunocruz, US). In order to be used to label the cells, the vaccine proteins are desorbed from the powders with 0.5M NaCl solution. They are then associated with a biotin using the kit ((Pierce Biotechnology kit, EZ-link™ sulfo-NHS-Biotinylation kit –thermo scientific) following the manufacturer's instructions. Biotin then reacts with a peroxidase associated with a streptavidin. Peroxidase is then demonstrated by a solution composed of diaminobenzidine (DAB) (0.05% DAB, 0.015% H<sub>2</sub>O<sub>2</sub>, 0.01M PBS, pH 7.2) maintained for less than five minutes in contact with the cells. The labeling is visible in the form of a coloration brown cells.

### 3 | RESULTS

8 dogs were euthanized for reasons related to the tumor (pain, change in tumor size, deterioration in general condition, convulsions), 1 for unrelated reasons and 1 is still alive when the paper was written, 2 were lost to follow-up. Three dogs had 2 to 4 cycles of vaccinations (Table 1). Dogs can be divided into two groups; a long survival group (n = 7, greater than 150 days) and a short survival group (n = 3, less than 150 days). In the latter group, two out of three dogs were euthanized at the owners' request for a pain problem not controlled by analgesics and non-steroidal anti-inflammatory drugs. In this group, euthanasia generally takes place within 45 days of treatment. which does not allow an immune reaction time to have an effect on the tumor.

dog	response			Death cause	side effects	Associated treatment	Vaccination number of cycles	stage
	Minor tumoral regression	OS	PFS					
ost1	yes	310	310	linked (convulsion)	0	analgesic	2	T1N1M0
ost2	n.a.	410	380	linked	0	amputation	1	T2N0M0
ost3	Yes	455	420	linked (dystrophy)	0	analgesic	2	T2N0M0
ost4	Yes	170	170	not linked	0	analgesic	1	T2N0M0
ost5	n.a.	210	200	Linked	0	amputation	1	T2N0M0
ost6	Yes	150	150	Linked	0	analgesic	1	T2N0M0
ost7	No	45	45	linked (pain)	0	analgesic	1	T2N1M0
ost8	n.a.	1015	1015	Not linked (embolism)	0	amputation	4	T2N0M0

ost9	Yes	45	0	linked (pain)	0	analgesic	1	T2N0M0
ost10	No	20	0	linked (convulsion)	0	analgesic	1	T2N1M1
ost11				Lost sight		analgesic	1	T2N1M1
ost12						analgesic	1	T2N1M0

Table 1: characteristics of the treatment of the dogs included in the study and evolution of the parameters measured, OS (overall survival) and PFS (progression free survival - survival without increase in tumor volume

All biopsies contained both gp96 and HSP 70. Few bands are detected by electrophoresis, and they are located in the 90,000 and 70,000 dalton regions (Fig. 1). On the other hand, the dot blots show a significant presence of gp96 and HSP70 on the surface of the HA beads (fig. 2).

Vaccine proteins labeled with peroxidase bind to RAW264 cells and binding was inhibited by anti gp91 (fig. 3).




Figure 1 : SDS Page of proteins (dog ost3, fourth column) detached from hydroxyapatite powders by washing in NaCl solutions (0.5M). We see two well-individualized bands at 97 and 70,000 kDa. First column is protein ladder

The average survival of the dogs of the first group (long survival) is 270 days, the median is 260 days. The mean and median of PFS were very close, 260 and 250 days respectively.




Figure 2 : dot blot of the solutions extracted from powders injected at ost9 and 10 (blots 1 and 2) marked with anti gp96 (top band) and anti HSP70 (bottom band).

Amputated dogs had an overall survival of 531 days while that of non-amputated dogs is 270 days, which was significant ( $p > 0.005$ ).

All dogs had a stable tumor size (SD) throughout their survival. There was an improvement in the inflammatory state of the tumor site after each injection. Two dogs for which survival was particularly long underwent a second round of vaccination.

Radiologically, the first stages (less than 2 months) of the vaccination are followed by remodeling of the tumor site with periosteal bone formation and densification of the osteolysis zone (Fig. 4).

It should be noted that all long-surviving dogs maintained good general condition with no change in weight for most of their survival.

#### 4 | DISCUSSION

In the long survival group, the results show a much better survival than what is published without treatment or by simple amputation. From a study on 400,000 dogs whose files were extracted from the file of a Swedish insurance company [26], it was shown that the average survival of dogs diagnosed with osteosarcoma is 56 days (table 2). Spotnick et al. [27], from 162 dogs treated by amputation, showed an average survival of 134 days. Lane et al [28] obtained a median survival of 231 days and a progression-free survival of 247 days from 33 amputated dogs and receiving chemotherapy combining doxorubicin and carboplatin. Recently, chemotherapeutic protocols combining amputation and carboplatin or doxorubicin have been published and show an improvement in survival compared to control groups with a median at 307 and 240 days respectively [29, 30]. The combination of the two molecules does not improve the prognosis [31].




Fig.3 : labeling of the cells with the vaccine proteins associated with a peroxidase before (A) and after (B) the blocking of cd91. Labeling controlled by gp96 before (B) and after (D) blocking of these same receptors. This labeling shows that at least some of the vaccine proteins bind to the cd91 receptors.. bar : 150 µm

The binding of certain vaccine proteins to CD91 shows that the injected doses contained active HSPs, more especially gp 96 and HSP70, since CD91 are specific receptors for these proteins. Protein binding to CD91 can be a test for vaccine activity that can be combined with an elispot-type CD8 stimulation test.

The effect of the injections on the inflammation of the tumor site is relatively reproducible. Nevertheless, at least in 2 cases of non-amputated dogs, pain motivated the request for euthanasia of the animal by its owners very early when the general and local condition did not justify it. Pain control is therefore a very sensitive parameter in non-amputated dogs.

Various techniques can be used *in vitro* to demonstrate the stimulation of CD8 by proteins, in oncology they are not necessarily representative of the effectiveness of vaccination [32]. We have shown that this therapeutic vaccination technique used in Balb / c mice to immunize them against 4T1 tumor cells cross-prime their CD8 against these cells. The latter synthesize IFN $\gamma$  when brought into contact *in vitro* with antigen-presenting cells stimulated *in vivo* by the vaccine.

The decrease in tumor volume in non-amputated dogs and after injection of the vaccines from the third injection for a period of about twenty days led the veterinarians to carry out several cycles of vaccination when only planned one initially. No side effects have been demonstrated, in particular no unexplained fever, itching or neurological disturbances which could have indicated sensitization to

healthy tissue molecules.



Figure 4 : dog ost3. Radiological changes 170 days apart. There is significant ossification of the area of initial osteolysis

The purification of gp96 and HSP70 is relatively good, but there are contaminating proteins bands at different molecular weights. It is therefore possible that proteins other than heat shock proteins are involved in building an immune response. The presence of gp96 and HSP70 is nevertheless constant. HSP70 is often a membrane protein [33] which is constitutional but which is removed in the purification procedure. There is a cytoplasmic HSP70 which is like gp96 expressed only during cellular stress [34]. The presence of these two stress proteins makes it possible to have in their associated molecules almost all the peptides synthesized by the cancer cell. In addition, these two proteins have a major role in the cross priming of CD8s. Gp96 even has a specific receptor (CD91) on dendritic cells. Srivastava's work has shown the benefits of using purified autologous gp96 in laboratory animals [35].

There are relatively few publications about the treatment of canine osteosarcomas by active immunotherapy. Much more experimentation has been done in the field of passive immunotherapy, in particular an autologous tumor vaccine whose cells express a GM-CSF transgene [36, 37]. Lung metastases from osteosarcoma have also been treated by injection of cationic liposomes containing DNA encoding IL-2 [38]. Similarly, sarcomas have been treated with injections of

irradiated xenogenic cells synthesizing GM-CSF and IL-2 mixed with a lysate of autologous or xenogeneic cells followed by injection of liposomes carrying genes of cIFN -b and HSVtk and ganciclovir [39 ]. These various and complex cytokine treatments have shown an improvement in the prognosis.

Dog number	traitement	Médian	auteur	stage
162	amputation	134,4	Spodnick GJ et al, J Am Vet Med Assoc. 1992 Apr 1;200(7):995-9	Not given
90	0	3	Boston SE, J Am Vet Med Assoc. 2006 Jun 15;228(12):1905-8.	stade III
	radio/chimio	130		
	amputation	76		
	amputation/chimio	78		
764	0	56	Agneta Egenvalin, Can J Vet Res. 2007 October; 71(4): 292–299	Not given
33	amputation/chimio	247	Lane A, et al. Aust Vet J 2012 Mar;90(3):69-74	Not given
155	Amputation/ Chimio (carboplatine)	307	Philips et al. J Am Anim Hosp Assoc 45(1):33–38	Not given
303	Amputation/ Chimio (doxorubicyn)	240	Moore, AS et al. J Vet Intern Med 21(4):783– 790	Not given

Table 2 : median overall survival in days of published canine osteosarcomas series according to treatment

The complexity of these treatments nevertheless makes them difficult to apply. The treatment of osteosarcomas by immunotherapy by injection of a cytotoxic human T cell line (TALL 104) [40] has given results which appeared interesting with a median survival of 11.5 months but difficult to interpret due to co-treatments by amputation and chemotherapy. Recently Mata et al [41] developed chimeric antigen receptor (CAR) T cells against Her2 receptors in dog osteosarcoma cells. These cells have shown *in vitro* an ability to eliminate canine osteosarcoma cells. The purification of autologous proteins from a lysate seemed to us much simpler and hence less risky. To our knowledge, our publication is the first using an immunotherapy method without association with chemotherapy and even with an unamputated group without backup surgery. However, it seems that amputation before vaccination provides a significant improvement in animal survival.

For technical reasons, we were unable to provide proof of CD8 activation in each dog in this series. On the other hand, the decrease in tumor size observed after

injection from the third in dogs without amputation is in favor of such activation, as has been shown in mice.

HA particles have long been used in adsorption chromatography columns, they have also been used as vaccination adjuvants [42, 43]. When injected subcutaneously, it causes a foreign body reaction leading to an influx of antigen-presenting cells which participate in this adjuvant effect. Placed in the presence of monocytes in culture, they have a very marked activating effect on the inflammasome [44] and also participate in the maturation of dendritic cells with the expression of co-factors necessary for the cross-priming of CD8s (unpublished results) .

## 5 | CONCLUSIONS

Although this series is short, this method for immune system stimulation appears to improve the prognosis of canine osteosarcoma with or without amputation. We did not note any side effects in particular of an autoimmune nature. The improvement is most noticeable when the dogs are amputated. These results were obtained without associated chemotherapy. We can therefore expect that the combination of cytotoxic treatments during a therapeutic window preserving the immunity of the animal could amplify the improvement in overall survival

## REFERENCES

- 1/ Mueller, F., Fuchs, B., Kaser-Hotz, B., Comparative biology of human and canine osteosarcoma. *Anticancer research* 27: 155-164, 2007
- 2/ Brissot, H., Bouvy, B., Ostéosarcome du chien et du chat. *Le point vétérinaire*, 36 : 116-122, 2005
- 3/ Egenval, A., Nødtvedt, A., von Euler, H., Bone tumors in a population of 400 000 insured Swedish dogs up to 10 y of age: incidence and survival, *The Canadian Journal of Veterinary Research* 71:292–299, 2007
- 4/ Green, T.F., Jaffe, E.M., Cancer vaccines. *Journal of Clinical Oncology* 17 (3):1047-1060, 1999.
- 5/ Hueman, M.T., Dehqanzada, Z.A., Novak, T.E., Gurney, J.M., Woll, M.J., Ryan, G.B., Storrer, C.E., Fisher, C., McLeod, D.G., Ioannides, C.G., Ponniah, S., Peoples, G.E., Phase IClinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients, *Clin Cancer Res* 2005;11(20)
- 6/ Ferrara, N., Hillan, K.J., Gerber, H.-P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nature Reviews Drug Discovery* 3, 391-400, 2004
- 7/ Dranoff G, GM-CSF-based cancer vaccines. *Immunol Rev*;188: 147-54, 2002

8/ Zarei, S., Schwenter, F., Luy, P., Aurrand-Lions, M., Morel, P., Kopf, M., Dranoff, G., Mach, N., Role of GM-CSF signaling in cell-based tumor immunization, *Blood*. 113:6658-6668, 2009

9/ Antony GK, Dudek AZ, Interleukin 2 in cancer therapy. *Curr Med Chem.* 17: 3297-302, 2010

10/ Lockyer, R.W., Gillat, D.A., BCG immunotherapy for superficial bladder cancer, *J R Soc Med*, 94:119-123, 2001.

11/ Oizumi, S., Strbo, N., Pahwa, S., Deyev, V., Podack, E.R., Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. *The Journal of Immunology* 179:2310-2317, 2007.

12/ Catros-Quemener, V., Bouet, F., Genetet, N., Immunité antitumorale et thérapies cellulaires du cancer. *medecine/sciences* 19:43-53, 2003.

13/ Y. Akiyama, R. Tanosaki, N. Inoue, M. Shimada, Y. Hotate, A. Yamamoto, N. Yamazaki, I. Kawashima, I. Nukaya, K. Takesako, K. Maruyama, Y. Takaue, and K. Yamagushi. Clinical response in japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. *Journail of Translational Medicine* 3:4-14, 2005.

14/ Okada,H.; Kohanbash,G.; Zhu,X.; Kastenhuber,E.R.; Hoji,A.; Ueda,R.; Fujita,M. Immunotherapeutic approaches for glioma, *Crit Rev Immunol*, 29: 1-42 2009

15/ Théoleyre,S.; Mori,K.; Cherrier,B.; Passuti,N.; Gouin,F.; Rédini,F.; Heymann,D. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as possible therapeutic approach of osteosarcoma. *BMC Cancer* 5:123-133, 2005.

16/ Kaiser, J., A detailed genetic portrait of the deadliest human cancers. *Science* 321:1280-1281, 2008.

17/ Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW, An integrated genomic analysis of human glioblastoma multiforme. *Science* ; 321(5897):1807-12, 2008.

18/Romanucci M, D'Amato G, Malatesta D, Bongiovanni L, Palmieri C, Ciccarelli A, Buracco P, Morello E, Maniscalco L, De Maria R, Martano M, Della Salda L. Heat shock protein expression in canine osteosarcoma. *Cell Stress Chaperones*. ;17:131-8, 2012.

19/ Arrigo, A-P , Chaperons moléculaires et repliement des protéines. L'exemple de certaines protéines de choc thermique. *medecine/sciences* 21:619-625, 2005.

20/ Ciocca, D.R., Calderwood, S.K., Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications *Cell Stress Chaperones*. 2005 June; 10(2): 86–103.

21/ Murshid A, Gong J, Calderwood SK, The role of heat shock proteins in antigen cross presentation, *Front Immunol.* ; 3:63 , 2012.

- 22/ Calderwood SK, Murshid A, Gong J, Heat shock proteins: conditional mediators of inflammation in tumor immunity. *Front Immunol.*;3:75, 2012
- 23/ Ozger H, Eralp L, Atalar AC, Toker B, Esberk Ates L, Sungur M, Bilgic B, Ayan I, The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis. *Acta Orthop Traumatol Turc* 43:28–34, 2009
- 24/ Uozaki H, Ishida T, Kakiuchi C, HoriuchiH, GotohT, IijimaT, Imamura T, Machinami R (2000) Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. *Pathol Res Pract* 196:665–673
- 25/ Trieb K, Lang S, Kotz R (2000) Heat-shock protein72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. *Pediatr Haematol Oncol* 17:355–364
- 26/ Egenvall, A., Nødtvedt, A., von Euler, H., Bone tumors in a population of 400 000 insured Swedish dogs up to 10 y of age: incidence and survival, *The Canadian Journal of Veterinary Research* 2007;71: 292–299.
- 27/ Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL , J Am Vet Med Assoc. 1992 Apr 1;200(7):995-9
- 28/ Lane A, Black M, Wyatt K, Toxicity and efficacy of a novel doxorubicin and carboplatin chemotherapy protocol for the treatment of canine appendicular osteosarcoma following limb amputation. *Aust Vet J.* 2012 Mar;90(3):69-74
- 29/ Phillips B, Powers BE, Dernell WS, Khanna, C, Hogge, GS, Vail, DM. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. *J Am Anim Hosp Assoc* 2009, 45: 33–38.
- 30/ Moore AS, Dernell WS, Ogilvie GK, Kristal O, Elmslie R, Kitchell B, Susaneck S, Rosenthal R, Klein MK, Obradovich J, Legembre A, Haddad T, Hahn K, Powers BE, Warren D (2007) Doxorubicin and BAY 12–9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. *J Vet Intern Med* 21(4):783– 790 Morello E, M
- 31/ Selman LE, Burton JH, Thamm DH, Withrow, SJ, Lana, SE, Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. *J Vet Intern Med* 2014, 28: 554–563
- 32/ Wolchok,J.D.; Hoos,A.; O'Day,S.; Weber,J.S.; Hamid,O.; Lebbé,C.; Maio,M.; Blinder,M.; Bohnsack,O.; Nichol,G.; Humphrey,R.; Hodis,F.S., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, *Clin Cancer Res*, 15: 7412-7420, 2009
- 33/ Rujano, M.A., Kampinga, H.H., The HSP70 chaperone machine as guardian of the proteome: implications for protein misfolding diseases. In: Radons, J., Multhoff, G., (eds). *Heat Shock Proteins in Biology and Medicine*, 2006, pp: 61-85. Research Signpost, Kerala, India
- 34/ Tamura, Y., Torigoe, T., Sato, N., Extracellular heat shock proteins in immune response: a guide for cross presentation. In: Radons, J., Multhoff, G., (eds). *Heat Shock Proteins in Biology and Medicine*, 2006, pp: 119-130. Research Signpost, Kerala, India

- 35/ Srivastava, P.K., DeLeo, A.B., Old, L.J., Tumor rejection antigens of chemically induced sarcomas of inbred mice. *Proc Natl Acad Sci* 83:3407-3411, 1986.
- 36/ Liliana, M.E., Finochiaro, M.S., Gil-Cardeza, M.L., Riveros, M.D., Glikin, G.C., Cytokine-enhanced vaccine and interferon- $\beta$  plus suicide gene as combined therapy for spontaneous canine sarcomas. *Research in Veterinary Science*. 2011; 91:230-234
- 37/ Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG., Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. *Hum Gene Ther.* 1998 Sep 1;9(13):1851-61
- 38/ Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggett D., Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. *Hum Gene Ther.* 2005 Aug;16(8):937-46.
- 39/ Finocchiaro LM, Glikin GC., Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. *Gene Ther.* 2008 Feb; 15(4):267-76.
- 40/ Visonneau S, Cesano A, Jeglum KA, Santoli D, Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104, *Clin Cancer Res.* 1999 (7):1868-75
- 41/ Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S, Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. *J Immunother.* 2014 37:407-15.
- 42/ Stanker L, Vanderlan, M., Juarez-Salina, S. H. One-Step Purification of Mouse Monoclonal Antibodies from Ascites Fluid By Hydroxylapatite Chromatography. *J. Immunol. Met.* 76(1) 1985: 157–169.
- 43/ He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ, Calcium phosphate nanoparticle adjuvant, *Clin Diagn Lab Immunol.* 2000 Nov;7(6):899-903.
- 44/ Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B, Vignery A, Eisenbarth SC, Flavell RA NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. *Proc Natl Acad Sci U S A.* 2011 108 ; 14867-72. .

## ÍNDICE REMISSIVO

### A

- Ácido peracético 116, 118, 119, 120, 122, 123, 124  
Adaptação 2, 4, 81, 163, 200  
AEC 102, 103, 104, 106, 109  
Análise 2, 5, 13, 22, 38, 39, 47, 50, 53, 70, 73, 88, 105, 106, 111, 114, 120, 125, 126, 129, 141, 145, 147, 148, 149, 155, 158, 178, 179, 198, 200, 202, 203, 206, 210, 230, 234, 238  
Anestesia 19, 20, 22, 23, 28, 29, 30, 97, 99, 118, 119, 121, 122, 124  
Anticoccidianos 84, 85, 89, 90, 92, 93, 94  
Antimicrobianos 110, 111, 113, 122, 165, 169

### B

- Bactéria 12, 112  
Barbatimão 161, 162, 164, 165, 166, 167, 168, 169, 171, 172  
Bem-estar 2, 4, 139, 207  
Brita 31, 32, 33  
Búfalos 50, 54, 55, 58

### C

- Cão 15, 29, 31, 34, 38, 41, 77, 132, 134, 149, 150, 151  
Caprinocultura 2, 3  
Carrapatos 11, 13, 14, 15, 16, 17, 18  
Casco 97, 98, 100  
Cavalos 97, 100, 101  
Células 26, 38, 39, 40, 41, 47, 62, 65, 84, 85, 86, 87, 89, 90, 91, 133, 145, 146, 148, 149, 183, 184, 198, 205, 229, 231, 233, 234, 235  
Coccídeo 70, 74  
Componentes principais 210  
Corpo estranho 31, 32, 140  
Criopreservação 61, 62, 63, 65, 67

### D

- Descritores ambientais 210  
Desempenho zootécnico 84, 85  
Diagnóstico clínico 173

Diarreia 31, 33, 35, 36, 72, 74, 77, 78, 79, 140, 144

Doenças das aves 43, 93, 94, 95

## E

*Ehrlichia canis* 11, 12, 16, 17, 18

*Eimeria* spp 70, 71, 74, 76, 84, 94

Encefalopatias 152, 156, 159

Equinos 82, 97, 100, 101, 161, 162, 164, 165, 172

## F

Fatores de risco 11, 13, 15, 16, 55, 102, 103, 105, 107, 109, 143

Feridas de segunda intenção 161

Fluidoterapia ozonizada 77, 80, 81

## G

Gamopatia monoclonal 38

Gás ozônio 173, 174, 175, 176, 177, 179, 180, 181

Gatos 20, 27, 28, 29, 30, 32, 41, 116, 119, 123, 124, 132, 136, 145, 146, 230, 234, 238

Germoplasma 61, 62

Grupo 116, 119, 128, 184

## H

*Haemochus* spp 70, 71

## I

Imunoterapia 183, 184

Infecção bacteriana 97

Infecções respiratórias hospitalares 116

Insuficiência renal 77, 78, 82, 200

Intersexo 126, 131

IS1311 50, 52, 53, 54, 57

Isolamento 50, 52, 54, 55, 112, 113, 122

## M

Malignidade 149, 229, 233, 234

Mamite 173

Manejo sanitário 84

- Maranhão 1, 54, 58, 102, 103, 104, 105, 106, 107, 109, 240  
Mieloma múltiplo 38, 39, 40, 41

## N

- Necropsia 88, 97, 99, 126, 128, 137, 141, 142  
Neoplasia juvenil 132  
Neuropatia desmielinizante 43  
Noradrenalina 20, 24

## O

- Osteíte podal 97, 98, 99, 100  
Osteossarcoma 183, 184, 238  
Ovário 61, 114, 127  
Ovinocultura 9, 70, 71, 72, 75, 76  
Ozonioterapia 77, 78, 79, 80, 81, 82, 83

## P

- Paratuberculose 50, 51, 54, 58  
Patologia 31, 43, 45, 47, 51, 92, 110, 111, 128, 136, 173, 206, 208, 230, 236, 237  
Pele 3, 33, 35, 38, 40, 41, 44, 47, 122, 158, 161, 164, 165, 166, 170, 171, 172, 229, 232, 238  
Plantas medicinais 161, 163, 164, 165, 170  
Poodle 31, 32, 33, 147, 149  
Preguiça-comum 198, 201  
Prevalência 11, 12, 13, 72, 75, 102, 103, 105, 106, 107, 108, 110, 113, 236  
Prevenção 56, 84, 92, 106, 137, 155, 206  
Problemas digestivos 137

## R

- Rabdomiossarcoma 132, 133, 134, 135, 136  
Reprodução 60, 85, 86, 126, 131, 205, 240  
Resistência 26, 51, 71, 72, 74, 76, 81, 89, 90, 91, 110, 113, 114, 120, 123  
Ruminantes 1, 3, 7, 51, 55, 56, 71, 76, 108, 122, 137, 138, 139, 140, 144, 153, 155, 157, 158, 159

## S

- Sensibilidade 13, 74, 90, 93, 110, 111, 113, 124

Síndrome neurológica 43, 44, 157  
Sistema nervoso central 47, 152, 154, 159  
Sorologia 11  
Suíno 126, 128, 130  
Sustentável 93, 210

## T

Termorregulação 1, 2, 3, 129  
Tipificação 50, 52  
Tratamento 19, 20, 28, 31, 33, 35, 38, 39, 40, 55, 77, 78, 79, 80, 81, 82, 84, 97, 98, 101, 102, 104, 116, 117, 118, 119, 122, 134, 137, 140, 142, 147, 149, 150, 155, 156, 161, 163, 164, 165, 166, 167, 168, 169, 171, 172, 173, 174, 175, 176, 178, 179, 180, 181, 183, 184, 199, 200, 206  
Tubos endotraqueais 116, 119, 121, 123  
Tumor 133, 145, 147, 149, 150, 151, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 195, 196, 197, 229, 230, 231, 233, 238

## U

Urina 21, 22, 79, 132, 198, 199, 200, 201, 202, 203, 204, 205, 206

## V

Vacinação 44, 46, 48, 84, 90, 91, 92, 93  
Vasopressor 19, 20, 24  
Verminose 70, 71, 76  
Vesícula urinária 21, 22, 132, 133, 134, 135, 136  
Vigilância epidemiológica 152, 155, 157, 159  
Vômitos 31, 33, 36, 78, 81

# A Pesquisa nos Diferentes Campos da Medicina Veterinária 3

---

[www.atenaeditora.com.br](http://www.atenaeditora.com.br) 

[contato@atenaeditora.com.br](mailto:contato@atenaeditora.com.br) 

@atenaeditora 

[www.facebook.com/atenaeditora.com.br](https://www.facebook.com/atenaeditora.com.br) 

# A Pesquisa nos Diferentes Campos da Medicina Veterinária 3

---

[www.atenaeditora.com.br](http://www.atenaeditora.com.br) 

[contato@atenaeditora.com.br](mailto:contato@atenaeditora.com.br) 

@atenaeditora 

[www.facebook.com/atenaeditora.com.br](https://www.facebook.com/atenaeditora.com.br) 